Axsome Therapeutics, Inc. (AXSM) Form 10-Q — Nov 2, 2026
Axsome Therapeutics reported Q3 2026 total revenues of $259.7 million, up roughly 52% from $171.0 million a year earlier, driven by strong AUVELITY and SYMBRAVO sales plus an $8.5 million Pharmanovia milestone. Net loss narrowed dramatically to $12.9 million from $47.2 million in the prior-year quarter, with EPS improving to $(0.25) from $(0.94), putting the company within reach of profitability. Cash stood at $313.9 million at September 30, 2026, with $120 million of term loan principal outstanding (maturity May 2030) and the $70 million revolver balance repaid in October 2026; management says existing cash funds operations for at least twelve months.
Key figures
- Revenue
- 259691000
- Total Debt
- 130000000 (120000000 long-term term loan principal + 70000000 revolver, of which revolver repaid October 2026)
- Revenue Yoy
- +52% (Q3 2026 $259.7M vs Q3 2025 $171.0M)
- Total Assets
- 826773000
- Cash Position
- 313859000
- Shares Outstanding
- 52576839
- Loan maturity
- 2030-05-08
- Revolver rate
- SOFR + 4.00% (weighted average 8.07%)
- Term loan rate
- SOFR + 4.75% (effective 9.58%)
- Nine month revenue
- 669269000
- Accumulated deficit
- 1434694000
- Antecip royalty rate
- 3.0% of AUVELITY net sales
- Q3 product sales net
- 249951000
- Q3 2025 total revenue
- 170992000
- Pharmanovia milestone revenue q3
- 8514000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.